Neurogene Inc. is a clinical-stage company which bring life-changing genetic medicines to patients and families affected by rare neurological diseases. Neurogene Inc., formerly known as Neoleukin Therapeutics Inc., is based in NEW YORK.
| Revenue (Most Recent Fiscal Year) | $0.93M |
| Net Income (Most Recent Fiscal Year) | $-75.14M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.92 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -8742.70% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -36.16% |
| Return on Assets (Trailing 12 Months) | -32.51% |
| Current Ratio (Most Recent Fiscal Quarter) | 21.03 |
| Quick Ratio (Most Recent Fiscal Quarter) | 21.03 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $20.46 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.08 |
| Earnings per Share (Most Recent Fiscal Year) | $-4.28 |
| Diluted Earnings per Share (Trailing 12 Months) | $-4.35 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 14.26M |
| Free Float | 12.60M |
| Market Capitalization | $267.27M |
| Average Volume (Last 20 Days) | 0.21M |
| Beta (Past 60 Months) | 1.56 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 11.64% |
| Percentage Held By Institutions (Latest 13F Reports) | 52.37% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |